Page 211 - 2021_03-Haematologica-web

Genome editing of donor-derived aβ+ T cells
Labanieh (Stanford University) for providing the CAR construct, the CD19-CAR idiotype-specific antibody and the Nalm6-GL and Raji-GL cell lines. The authors are also grateful to the Stanford Small Animal Imaging Facility, in which biolumines- cence imaging was performed, for providing training and access to equipment. The authors thank the Veterinary Service Center at Stanford Medicine for providing training and animal care and
Synthego for providing chemically modified sgRNA. VW was supported by fellowships from Deutsche Forschungsgemeinschaft (DFG) and Care-for-Rare Foundation (Germany). MHP thanks the Amon Carter Foundation, the Sutardja Foundation and the Laurie Kraus Lacob Faculty Scholar Award in Translational Research for support. MHP also thanks the Chan-Zuckerberg Biohub for support.
References
1.Schrappe M, Hunger SP, Pui C-H, et al. Outcomes after induction failure in child- hood acute lymphoblastic leukemia. N Engl J Med. 2012;366(15):1371-1381.
2. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogeneic transplan- tation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomi- sation in an international prospective study. Lancet. 2005;366(9486):635-642.
3. Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors – the ALL-SCT-BFM-2003 trial. J Clin Oncol. 2015;33(11):1265-1274.
4. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3): 555-562.
5. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host dis- ease in human recipients of allogeneic-mar- row grafts. N Engl J Med. 1979;300(19): 1068-1073.
6. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem- cell grafts in the U.S. Registry. N Engl J Med. 2014;371(4):339-348.
7.Chaleff S, Otto M, Barfield RC, et al. A large-scale method for the selective deple- tion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy. 2007;9(8):746-754.
8.Bertaina A, Zecca M, Buldini B, et al. Unrelated donor vs HLA-haploidentical alpha/beta T-cell and B-cell depleted HSCT in children with acute leukemia. Blood. 2018;132(24):2594-2607.
9. Lang P, Feuchtinger T, Teltschik H-M, et al. Improved immune recovery after transplan- tation of TCRaβ/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant. 2015;50(S2):S6-S10.
10. Locatelli F, Merli P, Pagliara D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after aβ T- cell and B-cell depletion. Blood. 2017;130 (5):677-685.
11. Locatelli F, Bauquet A, Palumbo G, Moretta F, Bertaina A. Negative depletion of a/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoi- etic stem cell transplantation. Immunol Lett. 2013;155(1-2):21-23.
12. Locatelli F, Pende D, Mingari MC, et al. Cellular and molecular basis of haploidenti- cal hematopoietic stem cell transplantation in the successful treatment of high-risk leukemias: role of alloreactive NK cells. Front Immunol. 2013;4:15.
13. de Witte MA, Kuball J, Miller JS. NK cells and gδT cells for relapse protection after allogeneic hematopoietic cell transplanta- tion (HCT). Curr Stem Cell Rep. 2017;3(4):301-311.
14. Klingebiel T, Cornish J, Labopin M, et al. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010;115(17):3437-3446.
15. Kongtim P, Lee DA, Cooper LJN, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical hematopoietic stem cell transplantation as platform for post-transplant cellular therapy. Biol Blood Marrow Transplant. 2015;21 (10):1714.
16. Lutz C, Massenkeil G, Nagy M, et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41(9):805- 812.
17. Liga M, Triantafyllou E, Tiniakou M, et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regi- men. Biol Blood Marrow Transplant. 2013;19(1):75-81.
18. Bader P, Klingebiel T, Schaudt A, et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allo- geneic SCT by early immunotherapy initiat- ed on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia. 1999;13(12):2079-2086.
19.Dominietto A, Pozzi S, Miglino M, et al. Donor lymphocyte infusions for the treat- ment of minimal residual disease in acute leukemia. Blood. 2007;109(11):5063-5064.
20. Lankester AC, Bierings MB, van Wering ER, et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal resid- ual disease level before stem cell transplan- tation. Leukemia. 2010;24(8):1462-1469. Willasch AM, Salzmann-Manrique E, Krenn T, et al. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experi- ence. Bone Marrow Transplant. 2017;52(2): 201-208.
1683.
24. Bonini C, Ferrari G, Verzeletti S, et al. HSV-
TK gene transfer into donor lymphocytes for control of allogeneic graft-versus- leukemia. Science. 1997;276(5319):1719- 1724.
25. Locatelli F, Ruggeri A, Merli P, et al. Administration of BPX-501 cells following Aβ T and B-cell-depleted HLA haploidenti- cal HSCT (haplo-HSCT) in children with acute leukemias. Blood. 2018;132(Suppl 1):307.
26. Majzner RG, Heitzeneder S, Mackall CL. Harnessing the immunotherapy revolution for the treatment of childhood cancers. Cancer Cell. 2017;31(4):476-485.
27. Rivière I, Sadelain M. Chimeric antigen receptors: a cell and gene therapy perspec- tive. Mol Ther. 2017;25(5):1117-1124.
28.Sadelain M. CD19 CAR T cells. Cell. 2017;171(7):1471.
29. Ruella M, Xu J, Barrett DM, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499- 1503.
30. Fraietta JA, Nobles CL, Sammons MA, et al. Disruption of TET2 promotes the therapeu- tic efficacy of CD19-targeted T cells. Nature. 2018;558(7709):307-312.
31. Nicholson IC, Lenton KA, Little DJ, et al. Construction and characterisation of a func- tional CD19 specific single chain Fv frag- ment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol. 1997;34(16-17):1157-1165.
32. Bak RO, Dever DP, Porteus MH. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc. 2018;13(2):358-376.
33.Haeussler M, Schönig K, Eckert H, et al. Evaluation of off-target and on-target scor- ing algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 2016;17(1):148.
34. Cradick TJ, Qiu P, Lee CM, Fine EJ, Bao G. COSMID: a web-based tool for identifying and validating CRISPR/Cas off-target sites. Mol Ther Nucleic Acids. 2014;3:e214.
35. Lee CM, Cradick TJ, Bao G. The Neisseria meningitidis CRISPR-Cas9 system enables specific genome editing in mammalian cells. Mol Ther. 2016;24(3):645-654.
36. MacLeod DT, Antony J, Martin AJ, et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol Ther. 2017;25(4):949-961.
37. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113-117.
38. Provasi E, Genovese P, Lombardo A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18(5):807-815.
39. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion
21.
22.
Anandi P, Tian X, Ito S, et al. Ex vivo T-cell– depleted allogeneic stem cell transplantation for hematologic malignancies: the search for an optimum transplant T-cell dose and T-cell add-back strategy. Cytotherapy. 2017;19(6): 735-743.
23. Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673-
haematologica | 2021; 106(3)
857